Lucid Diagnostics Files 2025 Proxy Statement
Ticker: LUCD · Form: DEF 14A · Filed: Apr 30, 2025 · CIK: 1799011
Sentiment: neutral
Topics: proxy-statement, governance, sec-filing
TL;DR
Lucid Diagnostics filed its proxy statement. Get ready to vote.
AI Summary
Lucid Diagnostics Inc. filed its definitive proxy statement (DEF 14A) on April 30, 2025, for the fiscal year ending December 31, 2024. The filing, which does not require a fee, outlines information for shareholders regarding the company's governance and upcoming decisions. The company's principal executive offices are located at 360 Madison Avenue, New York, NY.
Why It Matters
This filing is crucial for shareholders as it details important corporate governance matters and provides information necessary for them to vote on company proposals.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new financial information or material events.
Key Players & Entities
- Lucid Diagnostics Inc. (company) — Registrant
- 360 Madison Avenue, New York, NY (location) — Company Address
- April 30, 2025 (date) — Filing Date
- December 31, 2024 (date) — Fiscal Year End
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, also known as a definitive proxy statement, is used by companies to solicit shareholder votes on important corporate matters, such as the election of directors or executive compensation.
When was this proxy statement filed?
This definitive proxy statement was filed on April 30, 2025.
What is the fiscal year end for Lucid Diagnostics Inc. as reported in this filing?
The fiscal year end for Lucid Diagnostics Inc. is December 31.
Does Lucid Diagnostics Inc. have to pay a fee for this filing?
No, the filing indicates that no fee is required for this DEF 14A filing.
Where are Lucid Diagnostics Inc.'s principal executive offices located?
Lucid Diagnostics Inc.'s principal executive offices are located at 360 Madison Avenue, 25th Floor, New York, NY 10017.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 30, 2025 regarding Lucid Diagnostics Inc. (LUCD).